NCT01108705 - Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Brivanib

Tablets, Oral, 800 mg, once daily, until disease progression or toxicity

DRUG

Placebo

Tablets, Oral, 0mg, once daily, until disease progression or toxicity

Trial Locations (32)

333

Local Institution, Taoyuan District

833

Local Institution, Kaohsiung County

11217

Local Institution, Taipei

100021

Local Institution, Beijing

100071

Local Institution, Beijing

100853

Local Institution, Beijing

110001

Local Institution, Shenyang

130012

Local Institution, Changchun

130021

Local Institution, Changchun

150040

Local Institution, Harbin

200032

Local Institution, Shanghai

200080

Local Institution, Shanghai

210002

Local Institution, Nanjing

210029

Local Institution, Nanjing

215006

Local Institution, Suzhou

230022

Local Institution, Hefei

300060

Local Institution, Tianjin

308433

Local Institution, Singapore

310022

Local Institution, Hangzhou

350014

Local Institution, Fuzhou

350025

Local Institution, Fuzhou

400038

Local Institution, Chongqing

430023

Local Institution, Hankou

430030

Local Institution, Wuhan

510060

Local Institution, Guangzhou

510515

Local Institution, Guangzhou

610041

Local Institution, Chengdu

610080

Local Institution, Guanzhou

710000

Local Institution, Xi'an

710038

Local Institution, Xi'an

410-769

Local Institution, Gyeonggi-do

135-710

Local Institution, Seoul